• Explore /
  • Poster
  • / Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with <em>de novo </em>(M1) metastatic hormone-sensitive prostate cancer (mHSPC) versus progression to mHSPC (M0): Post hoc analysis of the phase III ARCHES trial.

Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with de novo (M1) metastatic hormone-sensitive prostate cancer (mHSPC) versus progression to mHSPC (M0): Post hoc analysis of the phase III ARCHES trial.

Abstract Video & Slides Poster

Authors

null

Arun Azad

Monash Health, Melbourne, Victoria, Australia

Arun Azad , Arnauld Villers , Boris Alekseev , Russell Zelig Szmulewitz , Antonio Alcaraz , Neal D. Shore , Daniel Peter Petrylak , Jeffrey Holzbeierlein , Francisco Gomez-Veiga , Brad Rosbrook , Fabian Zohren , Ho-Jin Lee , Gabriel P. Haas , Taro Iguchi , Arnulf Stenzl , Andrew J. Armstrong

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Prostate Cancer - Advanced Disease

Track

Prostate Cancer - Advanced

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02677896

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 102)

DOI

10.1200/JCO.2021.39.6_suppl.102

Abstract #

102

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Neal D. Shore

First Author: Andrew J. Armstrong

First Author: Andrew J. Armstrong

First Author: Andrew J. Armstrong